TopicalDosed ingredient Cosmetic cross-reference

Zinc Oxide

CAS 1314-13-2

Zinc Oxide (CAS 1314-13-2) is a Phase 4 pharmaceutical compound with 0 bioactivity targets and 1,827 adverse event associations.

SOURCE NLM DailyMed
Label records
6
SOURCE EMBL-EBI ChEMBL
Bioactivity
0
SOURCE DrugCentral
Adverse signals
1,827
SOURCE IUPHAR/BPS
PubMed IDs
0
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name
Zinc Oxide
CAS Number
1314-13-2
UNII
SOI2LOH54Z
InChIKey
RNWHGQJWIACOKP-UHFFFAOYSA-N
ChEMBL ID
CHEMBL3988900
Molecule Type
Small molecule
Source Match
EMBL-EBI ChEMBL (INCHIKEY)
Synonyms and normalized names
CI 77947
black box warningdosed ingredienttopical
SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 4 (Approved)
Approved or marketed human pharmaceutical use is represented in the source phase field.
ChEMBL CHEMBL3988900 | Small molecule
SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →
SOURCE NLM DailyMed 6 label rows

Drug Label Active Ingredients

Active ingredient and active moiety rows from source drug product labels.

ProductIngredient Active MoietyEffective
AOAO Acne Buster Salicylic Acid Drying Serum ZINC OXIDE
SOI2LOH54Z
 ZINC OXIDE 20260506
Neutrogena MINERAL UV TINT FACE MEDIUM DEEP SPF 30 ZINC OXIDE
SOI2LOH54Z
 ZINC OXIDE 20260505
PEGO Acne Buster Salicylic Acid Drying Serum ZINC OXIDE
SOI2LOH54Z
 ZINC OXIDE 20260505
PROSKI SOOTHE ZINC OXIDE
SOI2LOH54Z
 ZINC OXIDE 20260505
PROSKI ZINCO SKIN PROTECTANT ZINC OXIDE
SOI2LOH54Z
 ZINC OXIDE 20260504
Sky and Sol Face and Body Sunscreen SPF 50 ZINC OXIDE
SOI2LOH54Z
 ZINC OXIDE 20260330
SOURCE DrugCentral 80 associations

Adverse Event Associations

DrugCentral / FAERS disproportionality signal rows matched to this compound.

Reaction PTDrug AE LLRMedDRA
Pemphigus 5388 2914.407 10034280
Systemic lupus erythematosus 5706 2821.213 10042945
Glossodynia 4942 2463.73 10018388
Hand deformity 4327 2094.105 10061194
Arthropathy 5580 2011.374 10003285
Rheumatoid arthritis 5896 1957.092 10039073
Alopecia 6620 1818.384 10001760
Abdominal discomfort 6672 1707.992 10000059
Wound 4153 1696.508 10052428
Maternal exposure during pregnancy 4713 1668.79 10071408
Synovitis 4242 1494.37 10042868
Joint swelling 6343 1406.029 10023232
Contraindicated product administered 4745 1381.536 10078504
Anti-cyclic citrullinated peptide antibody positive 2939 1311.133 10068798
Toxicity to various agents 922 1308.684 10070863
Swelling 5394 1294.373 10042674
Infusion related reaction 5397 1287.898 10051792
Pain 11736 1247.172 10033371
Completed suicide 156 1247.137 10010144
Discomfort 3768 1237 10013082
Pericarditis 3222 1230.391 10034484
Arthralgia 9344 983.838 10003239
Death 2917 962.303 10011906
Drug abuse 118 850.231 10013654
Duodenal ulcer perforation 2089 833.438 10013849
Helicobacter infection 2154 806.912 10054263
Rheumatoid factor positive 1968 797.005 10039080
Drug interaction 1409 768.573 10013710
Drug intolerance 5244 756.546 10061822
Hepatic enzyme increased 3802 745.197 10060795
Musculoskeletal stiffness 3637 739.324 10052904
Exposure during pregnancy 2942 721.689 10073513
Product use issue 4348 710.902 10076309
Psoriatic arthropathy 2164 697.724 10037162
Therapeutic product effect decreased 3518 642.12 10082201
Acute kidney injury 2292 558.418 10069339
Intentional overdose 111 553.74 10022523
Treatment failure 3592 517.327 10066901
Febrile neutropenia 782 469.842 10016288
Disease progression 703 459.491 10061818
Nasopharyngitis 4157 459.13 10028810
Hypersensitivity 4429 426.497 10020751
Knee arthroplasty 1243 426.42 10023469
Overdose 632 410.016 10033295
Hip arthroplasty 1112 404.869 10020096
Foetal exposure during pregnancy 1800 390.809 10071404
Impaired healing 1876 377.935 10021519
Rheumatic fever 970 369.537 10039054
Suicide attempt 143 364.684 10042464
C-reactive protein abnormal 1081 351.094 10068559

Association rows are source-linked signal records, not incidence rates or clinical causality claims.

SOURCE NLM RxNorm 5 name rows

Drug Names / RxNorm

Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.

NameRxCUI TypeSource
CI 77947 11423 SU MTHSPL
ZINC OXIDE 11423 SU MTHSPL
Zinc Oxide 11423 SU MTHSPL
Zinc oxide 11423 SU MTHSPL
zinc oxide 11423 IN RXNORM
SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Zinc Oxide used for in pharmaceutical contexts?

Zinc Oxide (CAS 1314-13-2) appears in DailyMed active-ingredient label rows, including AOAO Acne Buster Salicylic Acid Drying Serum, Neutrogena MINERAL UV TINT FACE MEDIUM DEEP SPF 30, PEGO Acne Buster Salicylic Acid Drying Serum.

What are the known adverse events for Zinc Oxide?

Zinc Oxide has 1,827 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Pemphigus, Systemic lupus erythematosus, Glossodynia, Hand deformity, Arthropathy. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Zinc Oxide also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Zinc Oxide with EU status "restricted".

What clinical phase is Zinc Oxide in?

Zinc Oxide is rendered with ChEMBL max phase 4 (approved).